Glucagon‐like peptide‐1 (GLP‐1) receptor agonists in type 2 diabetes and long‐term complications: FOCUS on retinopathy.

The article discusses that seven placebo-controlled cardiovascular outcomes trials (CVOTs) of glucagon-like peptide-1 receptor agonists shown the class of drugs reduces cardiovascular risk and all-cause mortality in people with type 2 diabetes. It mentions that rapidity of glucose control improvement in people with pre-existing retinopathy. It also mentions that hypotheses regarding early worsening of diabetic retinopathy remain to be clarified.